Foresite Capital Management IV

Latest statistics and disclosures from Foresite Capital Management IV's latest quarterly 13F-HR filing:

Tip: Access up to 7 years of quarterly data

Positions held by Foresite Capital Management IV consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Portfolio Holdings for Foresite Capital Management IV

Companies in the Foresite Capital Management IV portfolio as of the December 2020 quarterly 13F filing

Company (Ticker) Portfolio Weight Valued At Change in Shares Share Count Share Price
Kinnate Biopharma (KNTE) 41.8 $385M NEW 9.7M 39.78
Keros Therapeutics (KROS) 10.8 $100M 1.4M 70.54
Relay Therapeutics (RLAY) 9.7 $89M 2.1M 41.56
Alx Oncology Hldgs (ALXO) 9.1 $84M 974k 86.20
Nurix Therapeutics (NRIX) 8.4 $77M 2.3M 32.88
Kura Oncology (KURA) 6.4 $59M +38% 1.8M 32.66
Olema Pharmaceuticals (OLMA) 4.3 $39M NEW 818k 48.08
Cytokinetics (CYTK) 3.2 $30M -14% 1.4M 20.78
Generation Bio (GBIO) 2.6 $24M 858k 28.35
Vaxcyte (PCVX) 1.3 $12M 466k 26.57
Cymabay Therapeutics (CBAY) 1.1 $10M 1.8M 5.74
Aclaris Therapeutics (ACRS) 0.7 $6.2M +556% 951k 6.47
Therapeutics Acquisition Corp Com Cl A (RACA) 0.5 $4.9M 350k 13.92

Past Filings by Foresite Capital Management IV

SEC 13F filings are viewable for Foresite Capital Management IV going back to 2017